Syneos Health Podcast | Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month

Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (AMD). By the age of 75, roughly 1 in 3 people living in the United States will have some form of AMD, and about 1 in 4 of those will have a vision-threatening, late-stage form of AMD. These statistics underscore the need for heightened public awareness and increased accessibility to innovative treatments.

February is Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month. In this episode, Laszlo Bekesi, MD, Vice President of Strategy and Innovation, and Jonathan Angelastro, Executive Director of Project Delivery at Syneos Health provide valuable insights into the evolving field of ophthalmology and the efforts to address the growing burden of age-related vision impairment—with a  focus on understanding both wet and dry AMD types, the complexities of AMD, its impact on vision and the urgency for early detection and treatment. They also discuss the current landscape of research and development in the space and highlight the opportunities for—and inherent operational challenges of—conducting clinical trials in ophthalmology.

For more insights and information on our ophthalmology expertise, check out:

Ophthalmology: Collaborating to Restore Vision and Improve Lives

Navigating Biometrics Challenges in Ophthalmology Clinical Trials: Lessons Learned

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.